VTR Ventas Inc

Ventas is a healthcare REIT owning senior housing communities, medical office buildings, and life sciences facilities, targeting operators serving aging adult populations. Sector: Real Estate.

Ventas Inc (VTR) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 3.48%, WACC is 7.66%, and the economic spread is -4.17%. On balance, the economic spread is negative, indicating that at current return levels, reinvestment is value-destructive in aggregate. Supporting metrics show ROE at 2.15% and ROA at 1.56%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that likely needs operating improvement before returns quality can be considered durable.

Valuation currently screens at trailing P/E of 154.20, forward P/E of 114.91, PEG of 437.82. The gap between trailing and forward multiples is wide, suggesting the market is pricing meaningful earnings expansion over the coming year. At this PEG level, the company is priced generously relative to its expected earnings trajectory — execution risk is meaningfully priced in. The aggregate current ratio of 0.65 reflects tighter near-term liquidity — a factor worth monitoring if macro conditions tighten. The valuation profile here is neither obviously cheap nor dramatically expensive — a setup where the return case is built more on earnings delivery than on re-rating potential.

From gross to free cash flow, gross margin sits at 41.30%, operating margin at 15.40%, and free cash flow margin at 17.18%. At this gross margin level, the the company demonstrate adequate production efficiency without commanding premium pricing. The operating margin reading is healthy — adequate to support reinvestment without sacrificing profitability. The company's FCF margin is above average, pointing to the company with efficient capital deployment and durable cash generation. The margin profile is mixed, with some layers more resilient than others and less room for execution slippage.

Revenue momentum and analyst targets together paint a picture where the estimated 12-month price change of 3.84%, where target-based return potential appears limited without multiple expansion, while TTM revenue growth of -38.39% indicating revenue contraction that adds uncertainty to the forward earnings outlook. Reported revenue growth is the operational foundation; the analyst target spread shows what the market is willing to pay above it — and that premium can evaporate quickly if delivery slips. For investors, the central question is whether the operating momentum visible in revenues is durable enough to support the price appreciation implied by consensus targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The composite read is moderately constructive but uneven — in the absence of a clear catalyst, a neutral stance is well-supported by the data.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.